New hope for hard-to-treat blood cancer: combo therapy trial launches
NCT ID NCT07018050
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests several combinations of the experimental drug QLS32015 with other medicines in 160 people whose multiple myeloma has come back or stopped responding to prior therapy. The goal is to see which combination works best to shrink tumors and achieve deep remission. Participants will receive one of several drug combinations, and doctors will monitor response and side effects closely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?
- Can a new drug combo outsmart Hard-to-Treat myeloma?
- Engineered immune cells take on Hard-to-Treat myeloma
- Home infusion for myeloma drug passes early safety check
- New hope for multiple myeloma: phase 3 trial launches
- New CAR T-Cell therapy targets Hard-to-Treat myeloma